Skip to Content

Mark Ritter

From Human Oncology

Jump to: navigation, search

Ritter 2016.jpeg

Mark Ritter



    Phone: (608) 263-8500

    Mailing Address:
    K4/330, Bx0600 Clinical Science Center
    600 Highland Ave
    Madison, WI 53792


  • B.S., Physics, University of San Francisco
  • M.S., Nuclear Engineering, University of California, Berkeley
  • Ph.D., Nuclear Engineering, University of California, Berkeley
  • M.D., University of Miami School of Medicine


  • Investigation of biology and technology-driven optimization of treatment for prostate cancer

Fields of Interest

  • Treatment of prostate, bladder, testicular, esophageal, pancreatic and colorectal cancer.
  • Clinical trials in prostate, esophageal and rectal cancer.
  • Molecular predictors of treatment response in prostate and esophageal cancers.


Recent Publications

Jeff M Michalski, Colleen Lawton, Issam El Naqa, Mark Ritter, Elizabeth O'Meara, Michael J Seider, W Robert Lee, Seth A Rosenthal, Thomas Pisansky, Charles Catton, Richard K Valicenti, Anthony L Zietman, Walter R Bosch, Howard Sandler, Mark K Buyyounouski, Cynthia Ménard
Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.
Int. J. Radiat. Oncol. Biol. Phys.: 2010, 76(2);361-8

Paul M Harari, Mark A Ritter, Albert J van der Kogel
Obituary and Tribute to John "Jack" Francis Fowler, PhD, DSc (1925-2016).
Int. J. Radiat. Oncol. Biol. Phys.: 2017, 97(5);886-888

Skyler Bryce Johnson, Pamela R Soulos, Timothy D Shafman, Constantine A Mantz, Arie P Dosoretz, Rudi Ross, Steven E Finkelstein, Sean P Collins, Simeng Suy, Jeffrey V Brower, Mark A Ritter, Christopher R King, Patrick A Kupelian, Eric M Horwitz, Alan Pollack, Matthew C Abramowitz, Mark A Hallman, Sergio Faria, Cary P Gross, James B Yu
Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.
Radiother Oncol: 2016, 121(2);294-298

Jeffrey V Brower, Shuai Chen, Michael F Bassetti, Menggang Yu, Paul M Harari, Mark A Ritter, Andrew M Baschnagel
Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012.
Int. J. Radiat. Oncol. Biol. Phys.: 2016, 96(5);985-993

Zachary S Morris, Sandeep Saha, William J Magnuson, Brett A Morris, Jenna F Borkenhagen, Alisa Ching, Gayle Hirose, Vanesa McMurry, David M Francis, Paul M Harari, Rick Chappell, Stuart Tsuji, Mark A Ritter
Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Cancer: 2016, 122(16);2487-95

Jeffrey V Brower, Jeffrey D Forman, Patrick A Kupelian, Daniel G Petereit, Vinai Gondi, Colleen A Lawton, Nick Anger, Sandeep Saha, Rick Chappell, Mark A Ritter
Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer.
Radiother Oncol: 2016, 118(1);99-104

David F Jarrard, Michael L Blute, Mark A Ritter
Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer.
J. Clin. Oncol.: 2014, 32(35);3926-9

Jialu Yu, Nicholas Hardcastle, Kyoungkeun Jeong, Edward T Bender, Mark A Ritter, Wolfgang A Tomé
On voxel-by-voxel accumulated dose for prostate radiation therapy using deformable image registration.
Technol. Cancer Res. Treat.: 2015, 14(1);37-47

Kara Babaian, Matthew Truong, Jeremy Cetnar, Deanna S Cross, Fangfang Shi, Mark A Ritter, David F Jarrard
Analysis of urological procedures in men who died from prostate cancer using a population-based approach.
BJU Int.: 2013, 111(3 Pt B);E65-70

Tim J Kruser, David F Jarrard, Andrew K Graf, Sean P Hedican, David R Paolone, John D Wegenke, Glenn Liu, Heather M Geye, Mark A Ritter
Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence.
Cancer: 2011, 117(12);2629-36

Jarrod B Adkison, Derek R McHaffie, Søren M Bentzen, Rakesh R Patel, Deepak Khuntia, Daniel G Petereit, Theodore S Hong, Wolfgang Tomé, Mark A Ritter
Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
Int. J. Radiat. Oncol. Biol. Phys.: 2012, 82(1);184-90